Rao Zhengsheng, Wang Zhiling, Tang Ming, Zhang Keqin
Urinary Nephropathy Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Infect Drug Resist. 2023 Sep 29;16:6473-6486. doi: 10.2147/IDR.S427656. eCollection 2023.
There is no consensus on the optimal use of perioperative antibiotics prophylaxis after kidney transplantation, but there is a common trend to limit the duration of antibiotic use worldwide. Metagenomic next-generation sequencing (mNGS) has emerged as a novel technology for pathogen detection in clinical practice due to its noninvasive, rapid, precise and high susceptibility to detect infectious pathogens. However, data are lacking on whether mNGS analyses could be used to detect pathogens and guide anti-infection regimens in kidney transplant donors and recipients.
We conducted a retrospective study to review all clinic data of mNGS and traditional laboratory methods (TMs) for pathogen detection in kidney transplant recipients and their corresponding deceased donors from August 1, 2021 to October 30, 2022 in our center.
A total of 57 donors and 112 of their corresponding recipients were included. The antimicrobial strategy mainly depended on mNGS results combined with traditional pathogen culture and clinical conditions. The percentages of positive pathogen detected by mNGS in blood, urine, bronchoalveolar lavage fluid (BALF) and preservation fluids (PFs) were 50.9% (29/57), 35.1% (20/57), 84.2% (48/57) and 54.4% (31/57) respectively, and were 24.6% (14/57), 15.8% (9/57), 57.9% (33/57) and 14.1% (8/57) respectively when using TMs. mNGS could detected all of pathogens which were detected by TMs. However, samples with negative TMs testing can be additionally detected as positive by mNGS (15/43 in blood, 11/48 in urine, 15/24 in BALF and 23/49 in PFs). Drug resistance genes were detected in 9 donors by mNGS,which were consistent with 6 donors by TMs. There was only one case of donor-derived infection in this study.
This study showed that it is effective to combine mNGS with traditional pathogen detection methods and clinical features to develop optimal perioperative antimicrobial management strategies for deceased donor kidney transplantation.
肾移植围手术期抗生素预防的最佳使用尚无共识,但全球范围内限制抗生素使用时间是一种普遍趋势。宏基因组下一代测序(mNGS)作为一种新型技术已出现在临床实践中的病原体检测中,因其具有无创、快速、精确以及对检测感染性病原体的高敏感性。然而,关于mNGS分析是否可用于检测肾移植供体和受体中的病原体并指导抗感染方案的数据尚缺乏。
我们进行了一项回顾性研究,以回顾2021年8月1日至2022年10月30日在我们中心肾移植受者及其相应的已故供体中用于病原体检测的mNGS和传统实验室方法(TMs)的所有临床数据。
共纳入57名供体及其112名相应的受体。抗菌策略主要取决于mNGS结果结合传统病原体培养和临床情况。mNGS在血液、尿液、支气管肺泡灌洗液(BALF)和保存液(PFs)中检测到的阳性病原体百分比分别为50.9%(29/57)、35.1%(20/57)、84.2%(48/57)和54.4%(31/57),而使用TMs时分别为24.6%(14/57)、15.8%(9/57)、57.9%(33/57)和14.1%(8/57)。mNGS能够检测出TMs检测到的所有病原体。然而,TMs检测为阴性的样本可被mNGS额外检测为阳性(血液中15/43、尿液中11/48、BALF中15/24、PFs中23/49)。通过mNGS在9名供体中检测到耐药基因,与TMs检测的6名供体一致。本研究中仅1例供体源性感染。
本研究表明,将mNGS与传统病原体检测方法及临床特征相结合,为已故供体肾移植制定最佳围手术期抗菌管理策略是有效的。